PMID- 34354581
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210807
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a 
      Meta-analysis of Randomized Control Trials.
PG  - 652759
LID - 10.3389/fphar.2021.652759 [doi]
LID - 652759
AB  - Background: To update the efficacy and safety data of monoclonal antibodies for 
      the treatment of neuromyelitis optica spectrum disorders (NMOSD) and explore the 
      differences in the effect of treatment between patients seropositive and 
      seronegative for AQP4-IgG. METHODS: PubMed, Embase, and the Cochrane Library 
      published up to July 2020 were searched for randomized controlled trials (RCTs) 
      of monoclonal antibodies treatment (mAb) in patients with NMOSD. The primary 
      outcome was the hazard ratio (HR) for relapse. The secondary outcomes included 
      Expanded Disability Status Scale (EDSS) changes from baseline, adverse events 
      (AEs), and serious adverse events (SAEs). A random-effects model was applied for 
      the effect of heterogeneity among trials. RESULTS: We included 603 patients 
      (monoclonal antibody group, n=382, and control group, n=221) from seven RCTs. 
      There were fewer relapses in the mAb group (HR=0.32, 95% CI: 0.23-0.46, p<0.001), 
      as well as in the AQP4-IgG-seropositive patients (HR=0.18, 95% CI: 0.10-0.32, 
      p<0.001), but not in AQP4-IgG-seronegative NMOSD. Similar results were observed 
      when considering satralizumab only. The mAb had no impact on the changes in EDSS 
      scores from baseline (WMD=-0.21, 95% CI: -0.50-0.09, p=0.176). The mAb did not 
      lead to a higher frequency of AEs (OR=1.18, 95% CI: 0.70-1.98, p=0.529) or SAEs 
      (OR=0.99, 95% CI: 0.63-1.56, p=0.975) compared with the control group. 
      CONCLUSIONS: Compared to the control arm, monoclonal antibody therapy showed a 
      significantly better outcome in restraining the HR for relapse among patients 
      with NMOSD but insignificant effects in NMOSD patients with seronegative 
      APQ4-IgG. The safety profile in each arm had no significant difference.
CI  - Copyright (c) 2021 Kong, Wang, Zheng, Cai, Hua and Li.
FAU - Kong, Fanxin
AU  - Kong F
AD  - Encephalopathy and Phycology Department, Shenzhen Traditional Chinese Medicine 
      Hospital, ShenZhen, China.
AD  - Encephalopathy and Phycology Department, The Fourth Clinical Medical College of 
      Guangzhou University of Chinese Medicine, ShenZhen, China.
FAU - Wang, Jianjun
AU  - Wang J
AD  - Encephalopathy and Phycology Department, Shenzhen Traditional Chinese Medicine 
      Hospital, ShenZhen, China.
AD  - Encephalopathy and Phycology Department, The Fourth Clinical Medical College of 
      Guangzhou University of Chinese Medicine, ShenZhen, China.
FAU - Zheng, Haotao
AU  - Zheng H
AD  - Encephalopathy and Phycology Department, Shenzhen Traditional Chinese Medicine 
      Hospital, ShenZhen, China.
AD  - Encephalopathy and Phycology Department, The Fourth Clinical Medical College of 
      Guangzhou University of Chinese Medicine, ShenZhen, China.
FAU - Cai, Haobin
AU  - Cai H
AD  - Encephalopathy and Phycology Department, Shenzhen Traditional Chinese Medicine 
      Hospital, ShenZhen, China.
AD  - Encephalopathy and Phycology Department, The Fourth Clinical Medical College of 
      Guangzhou University of Chinese Medicine, ShenZhen, China.
FAU - Hua, Jun
AU  - Hua J
AD  - Department of Clinical Pharmacy, Shenzhen Traditional Chinese Medicine Hospital, 
      ShenZhen, China.
AD  - Department of Clinical Pharmacy, The Fourth Clinical Medical College of Guangzhou 
      University of Chinese Medicine, ShenZhen, China.
FAU - Li, Liling
AU  - Li L
AD  - Encephalopathy and Phycology Department, Shenzhen Traditional Chinese Medicine 
      Hospital, ShenZhen, China.
AD  - Encephalopathy and Phycology Department, The Fourth Clinical Medical College of 
      Guangzhou University of Chinese Medicine, ShenZhen, China.
LA  - eng
PT  - Journal Article
DEP - 20210720
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8329455
OTO - NOTNLM
OT  - eculizumab
OT  - inebilizumab
OT  - meta-analysis
OT  - neuromyelitis optica
OT  - rituximab
OT  - satralizumab
OT  - tocilizumab
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/07 06:00
MHDA- 2021/08/07 06:01
PMCR- 2021/07/20
CRDT- 2021/08/06 06:49
PHST- 2021/01/13 00:00 [received]
PHST- 2021/06/30 00:00 [accepted]
PHST- 2021/08/06 06:49 [entrez]
PHST- 2021/08/07 06:00 [pubmed]
PHST- 2021/08/07 06:01 [medline]
PHST- 2021/07/20 00:00 [pmc-release]
AID - 652759 [pii]
AID - 10.3389/fphar.2021.652759 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Jul 20;12:652759. doi: 10.3389/fphar.2021.652759. 
      eCollection 2021.